Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 3
1995 2
1996 1
1997 1
1998 2
1999 15
2000 30
2001 39
2002 36
2003 23
2004 25
2005 17
2006 17
2007 20
2008 16
2009 10
2010 10
2011 7
2012 14
2013 7
2014 8
2015 11
2016 12
2017 12
2018 9
2019 12
2020 13
2021 10
2022 8
2023 2
2024 5
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

380 results

Results by year

Filters applied: . Clear all
Page 1
Alosetron.
[No authors listed] [No authors listed] 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. 2019 Feb 7. Drugs and Lactation Database (LactMed®) [Internet]. Bethesda (MD): National Institute of Child Health and Human Development; 2006–. PMID: 30222295 Free Books & Documents. Review.
No information is available on the use of alosetron during breastfeeding. Because of relatively high protein binding and only moderate bioavailability, exposure of the breastfed infant is likely to be low. Until more data are available, alosetron should only be used …
No information is available on the use of alosetron during breastfeeding. Because of relatively high protein binding and only moderat …
Alosetron.
Butt I, Kasmin F. Butt I, et al. 2024 Jul 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. 2024 Jul 2. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan–. PMID: 31971721 Free Books & Documents.
Alosetron is a 5-HT3 receptor antagonist that treats severe diarrhea-predominant irritable bowel syndrome (IBS-D). ...Understanding alosetron's pharmacological features significantly enhances healthcare professionals' ability to tailor treatment plans to individual …
Alosetron is a 5-HT3 receptor antagonist that treats severe diarrhea-predominant irritable bowel syndrome (IBS-D). ...Understanding …
Alosetron.
Balfour JA, Goa KL, Perry CM. Balfour JA, et al. Drugs. 2000 Mar;59(3):511-8; discussion 519-20. doi: 10.2165/00003495-200059030-00008. Drugs. 2000. PMID: 10776833 Review.
Alosetron was most effective in female patients and particularly in those with diarrhoea-predominant IBS. In patients with IBS and healthy volunteers who received alosetron, the most common adverse event was constipation....
Alosetron was most effective in female patients and particularly in those with diarrhoea-predominant IBS. In patients with IBS and he …
Alosetron and irritable bowel syndrome.
Mayer EA, Bradesi S. Mayer EA, et al. Expert Opin Pharmacother. 2003 Nov;4(11):2089-98. doi: 10.1517/14656566.4.11.2089. Expert Opin Pharmacother. 2003. PMID: 14596662 Review.
Alosetron shows a greater effectiveness in women, and the role of genetic factors underlying inter-individual differences in the response to alosetron is currently under investigation. ...The impact of alosetron on QOL in IBS patients and the safety of treatm …
Alosetron shows a greater effectiveness in women, and the role of genetic factors underlying inter-individual differences in the resp …
Alosetron for severe diarrhea-predominant irritable bowel syndrome: improving patient outcomes.
Bleser S. Bleser S. Curr Med Res Opin. 2011 Mar;27(3):503-12. doi: 10.1185/03007995.2010.547933. Epub 2011 Jan 6. Curr Med Res Opin. 2011. PMID: 21208139 Review.
Alosetron is the only agent approved by the US Food and Drug Administration for treatment of severe IBS-D in women. ...In the subset of women who suffer from IBS-D, targeted serotonergic therapy with alosetron has been shown to provide symptom relief across multiple …
Alosetron is the only agent approved by the US Food and Drug Administration for treatment of severe IBS-D in women. ...In the subset …
Alosetron.
Mucke H, Cole P, Rabasseda X. Mucke H, et al. Drugs Today (Barc). 2000 Sep;36(9):595-607. doi: 10.1358/dot.2000.36.9.593776. Drugs Today (Barc). 2000. PMID: 12847565
Alosetron, a 5-HT(3)-receptor antagonist that is very closely related to ondansetron in terms of both chemistry and pharmacology, is the first compound of this type to be developed for irritable bowel syndrome. Clinical data for up to 3 months of treatment indicate that …
Alosetron, a 5-HT(3)-receptor antagonist that is very closely related to ondansetron in terms of both chemistry and pharmacology, is …
Pharmacology and clinical experience with alosetron.
Camilleri M. Camilleri M. Expert Opin Investig Drugs. 2000 Jan;9(1):147-59. doi: 10.1517/13543784.9.1.147. Expert Opin Investig Drugs. 2000. PMID: 11060667 Review.
There are some gender differences in the pharmacokinetic profile, with 30 - 50% higher alosetron concentrations in females. No consistent differences in alosetron serum concentrations between the young and elderly were observed. The pharmacokinetics of single, oral …
There are some gender differences in the pharmacokinetic profile, with 30 - 50% higher alosetron concentrations in females. No consis …
AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea.
Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. Lembo A, et al. Gastroenterology. 2022 Jul;163(1):137-151. doi: 10.1053/j.gastro.2022.04.017. Gastroenterology. 2022. PMID: 35738725
The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conducted an evidence review of the following agents: eluxadoline, rifaximin, alosetron, loperamide, tricyclic antidepressants, selective se …
The technical review panel prioritized clinical questions and outcomes according to their importance for clinicians and patients and conduct …
Alosetron in irritable bowel syndrome: strategies for its use in a common gastrointestinal disorder.
Lembo A, Weber HC, Farraye FA. Lembo A, et al. Drugs. 2003;63(18):1895-905. doi: 10.2165/00003495-200363180-00002. Drugs. 2003. PMID: 12930162 Review.
In this leading article, we present the current data on the pharmacology, clinical trials, indications and adverse effects of alosetron, a potent and selective 5-HT3 antagonist. As a result of the recognition of serious adverse effects, the indication for alosetron …
In this leading article, we present the current data on the pharmacology, clinical trials, indications and adverse effects of alosetron …
Functional bowel disorders with diarrhoea: Clinical guidelines of the United European Gastroenterology and European Society for Neurogastroenterology and Motility.
Savarino E, Zingone F, Barberio B, Marasco G, Akyuz F, Akpinar H, Barboi O, Bodini G, Bor S, Chiarioni G, Cristian G, Corsetti M, Di Sabatino A, Dimitriu AM, Drug V, Dumitrascu DL, Ford AC, Hauser G, Nakov R, Patel N, Pohl D, Sfarti C, Serra J, Simrén M, Suciu A, Tack J, Toruner M, Walters J, Cremon C, Barbara G. Savarino E, et al. United European Gastroenterol J. 2022 Jul;10(6):556-584. doi: 10.1002/ueg2.12259. Epub 2022 Jun 13. United European Gastroenterol J. 2022. PMID: 35695704 Free PMC article. Review.
A weak or conditional recommendation was achieved for antispasmodics, probiotics, tryciclic antidepressants, bile acid sequestrants, 5-hydroxytryptamine-3 antagonists (i.e. alosetron, ondansetron, or ramosetron). A multinational group of European experts summarized the cur …
A weak or conditional recommendation was achieved for antispasmodics, probiotics, tryciclic antidepressants, bile acid sequestrants, 5-hydro …
380 results